Epigenetic Silencing of HER2 Expression during Epithelial-Mesenchymal Transition Leads to Trastuzumab Resistance in Breast Cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Epigenetic Silencing of HER2 Expression during Epithelial-Mesenchymal Transition Leads to Trastuzumab Resistance in Breast Cancer
Authors
Keywords
-
Journal
Life-Basel
Volume 11, Issue 9, Pages 868
Publisher
MDPI AG
Online
2021-08-25
DOI
10.3390/life11090868
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation
- (2019) Babak Nami et al. Cancers
- The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
- (2018) Hamid Maadi et al. BMC CANCER
- Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
- (2018) Babak Nami et al. Cancers
- HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance
- (2017) et al. Cancers
- Epithelial-mesenchymal transition in patients with HER2+ metastatic breast cancer.
- (2017) A. Giordano et al. JOURNAL OF CLINICAL ONCOLOGY
- Cistrome Data Browser: a data portal for ChIP-Seq and chromatin accessibility data in human and mouse
- (2016) Shenglin Mei et al. NUCLEIC ACIDS RESEARCH
- The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes
- (2016) Bernard Pereira et al. Nature Communications
- 4DGenome: a comprehensive database of chromatin interactions
- (2015) Li Teng et al. BIOINFORMATICS
- HER2 induced EMT and tumorigenicity in breast epithelial progenitor cells is inhibited by coexpression of EGFR
- (2015) S Ingthorsson et al. ONCOGENE
- HER2-directed therapy: current treatment options for HER2-positive breast cancer
- (2015) Shahid Ahmed et al. Breast Cancer
- Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts
- (2015) Sílvia Cufí et al. Oncotarget
- P95 HER2 fragments and breast cancer outcome
- (2014) Deniz Tural et al. Expert Review of Anticancer Therapy
- Loss of E-cadherin expression is not a prerequisite for c-erbB2-induced epithelial-mesenchymal transition
- (2014) GISELA M.A. NILSSON et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Exploring long-range genome interactions using the WashU Epigenome Browser
- (2013) Xin Zhou et al. NATURE METHODS
- Methylation of the Claudin 1 Promoter Is Associated with Loss of Expression in Estrogen Receptor Positive Breast Cancer
- (2013) Francescopaolo Di Cello et al. PLoS One
- Spontaneous Epithelial-Mesenchymal Transition and Resistance to HER-2-Targeted Therapies in HER-2-Positive Luminal Breast Cancer
- (2013) David Lesniak et al. PLoS One
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin)
- (2012) Cristina Oliveras-Ferraros et al. CELL CYCLE
- Epithelial-Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer
- (2012) A. Giordano et al. MOLECULAR CANCER THERAPEUTICS
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- p95HER2 and Breast Cancer
- (2011) J. Arribas et al. CANCER RESEARCH
- Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein
- (2011) Kathleen Aertgeerts et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Dynamic emergence of the mesenchymal CD44posCD24neg/low phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin)
- (2010) Cristina Oliveras-Ferraros et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells
- (2010) Katri Köninki et al. CANCER LETTERS
- Combined inhibitory effect of formestane and herceptin on a subpopulation of CD44+/CD24low breast cancer cells
- (2010) Carla Cavaliere et al. CANCER SCIENCE
- Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models
- (2010) H. Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- ConceptGen: a gene set enrichment and gene set relation mapping tool
- (2009) Maureen A. Sartor et al. BIOINFORMATICS
- Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer
- (2009) Karin Rennstam et al. BREAST CANCER RESEARCH AND TREATMENT
- Immunoselection of Breast and Ovarian Cancer Cells with Trastuzumab and Natural Killer Cells: Selective Escape of CD44high/CD24low/HER2low Breast Cancer Stem Cells
- (2009) F. Reim et al. CANCER RESEARCH
- Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL
- (2009) L. Liu et al. CANCER RESEARCH
- Tissue-Specific Promoters Active in CD44+CD24-/low Breast Cancer Cells
- (2008) G. J. Bauerschmitz et al. CANCER RESEARCH
- The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
- (2008) Sendurai A. Mani et al. CELL
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More